linjc16/ctgov huggingface dataset:
Effect of Orthokeratology on Myopia Progression in French Children

Study Overview
=================
Brief Summary
-----------------
To evaluate and to compare the effect of orthokeratology (OK) on axial elongation in French myopic children.

Official Title
-----------------
Effect of Orthokeratology on Myopia Progression in French Children

Conditions
-----------------
Myopia Progression

Intervention / Treatment
-----------------
* Device: orthokeratology
* Device: single-vision spectacle correction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 7 to 17 years old Myopia between 0,50 D and 7.00 D Astigmatism ≤ 4.00 D with-the-rule 180+-20 Anisometropia ≤ 1.50 D Myopia evolution ≥ 0.25 D over 6 months Best-corrected visual acuity (BCVA) ≥ 20/20 (Snellen equivalent) Follow-up period > 6 months Exclusion Criteria: Prior history of any other myopia control treatment (except for single vision distance spectacles) Contraindication for contact lens wear or orthokeratology Preexisting ocular (amblyopia, strabismus, ocular inflammation, trauma, or surgery) or systemic disease Poor compliance to lens wear, examination or follow-up

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Orthokeratology treatment<br> | Device: orthokeratology<br>* rigid contact lenses<br>|
| single-vision spectacle correction<br> | Device: single-vision spectacle correction<br>* simple wear of spectacle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in axial length at one year |  | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in refractive error |  | one year | 
| changes in choroidal thickness |  | one year |
A Prospective Cohort Study on the Prediction of PHLF by Comparing the Prediction Model Based on VEGFA and PEDF With Indocyanine Green Clearance Test

Study Overview
=================
Brief Summary
-----------------
This study is a prospective cohort study. It is intended to develop a liver failure prediction model with high prediction efficiency by combining the content of VEGFA and PEDF in liver or serum with traditional pathophysiological indicators. Compare the prediction efficiency of the model with the previous liver failure prediction evaluation method, indocyanine green clearance test, to clarify its prediction ability and accurately predict postoperative liver failure.

Official Title
-----------------
A Prospective Cohort Study on the Prediction of PHLF by Comparing the Prediction Model Based on VEGFA and PEDF With Indocyanine Green Clearance Test

Conditions
-----------------
Liver Failure After Operative Procedure

Intervention / Treatment
-----------------
* Procedure: Extensive hepatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Extensive hepatectomy in our hospital（≥ three Hepatic segment） Exclusion Criteria: Serious basic diseases Intolerable surgery Refuse to perform ICG test before operation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Extensive hepatectomy<br> | Procedure: Extensive hepatectomy<br>* Extensive hepatectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative liver failure |  | 1-5 days after surgery |
Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.

Official Title
-----------------
Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Conditions
-----------------
Healthy Adult Males Volunteers

Intervention / Treatment
-----------------
* Drug: STN1012600 ophthalmic solution 0.002%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who can comply with scheduled visits and the examination and observation as specified in the clinical study protocol Exclusion Criteria: Subjects have a disease and/or abnormal laboratory value which is considered inappropriate from safety evaluation perspective Subjects who are inappropriate as participants in this study in the opinion of the investigator or sub investigator

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: STN1012600 0.002%<br> | Drug: STN1012600 ophthalmic solution 0.002%<br>* 1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Plasma Concentration [Cmax] | Calculate plasma pharmacokinetic parameters and study pharmacokinetics. | 1 week, Day 1 and Day 7 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under The Curve From Time Zero to the Last Sampling Time [AUC 0-t] | Calculate plasma pharmacokinetic parameters and study pharmacokinetics. | 1 week, Day 1 and Day 7 |
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

Study Overview
=================
Brief Summary
-----------------
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.

Official Title
-----------------
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

Conditions
-----------------
Sickle Cell Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Any patient with diagnosis of SCD based on high-performance liquid chromatography (HPLC) or hemoglobin electrophoresis at treating institution Treatment order for crizanlizumab; Index date was defined as the date for the first crizanlizumab treatment At least 12 months of available electronic medical record (EMR) data pre-index date (baseline) Patients must have received at least one dose of crizanlizumab For inclusion in pre/post analysis of effectiveness, patients must have received at least 6 doses of medication. The rates could be annualized if total post-index time was <12 months. Exclusion criteria: None specified

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) prior to treatment with crizanlizumab |  | Up to 12 months | 
| Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) during treatment with crizanlizumab |  | Up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who discontinued treatment with crizanlizumab |  | Up to 24 months | 
| Number of doses of crizanlizumab for patients who discontinued treatment with crizanlizumab |  | Up to 24 months | 
| Reasons for early discontinuation of crizanlizumab treatment |  | Up to 24 months | 
| Number of sickle cell disease (SCD)-related hospitalizations |  | Up to 24 months | 
| Number of SCD-related emergency department (ED) visits |  | Up to 24 months |
Neuromuscular Ultrasonography Assessment of Optic Nerve in Systemic Lupus Eryhematosus

Study Overview
=================
Brief Summary
-----------------
assessing the role of neuromuscular ultrasound in optic nerve involvement in systemic lupus patients.

Detailed Description
-----------------
Evaluating the role of neuromuscular ultrasound in optic nerve involvement in systemic lupus patients.by measuring the diameter of optic nerve at certain site and comparing it to healthy subjects measurements and to asses NMUS ability to detect optic neuropathy in lupus patients in comparison to conventional techniques including opthalmologist evaluation and visual evoked potential

Official Title
-----------------
Neuromuscular Ultrasonography Assessment of Optic Nerve in SLE

Conditions
-----------------
Optic Neuropathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult group of SLE patients, who fulfilled Systemic Lupus International Collaborating Clinics classification criteria for SLE (SLICC) with or without symptoms of optic neuropathy another group of apparently healthy subjects with no. history of chronic conditions Exclusion Criteria: Any patient with optic neuritis due to causes other than lupus was excluded from the study: ex. Post traumatic neuropathy Purely degenerative neuropathy Diabetic neuropathy Toxic neuropathy Neuropathies related to infections Drug induced neuropathy e.g: quinine and some antibiotics, ethambutol Infections e.g. measles, mumps, Lyme disease, etc. Other Autoimmune diseases like sarcoidosis, B.D Tumor causing Inc. intracranial tension.

Ages Eligible for Study
-----------------
Minimum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparing diameter (in mm2) of optic nerve in SLE patients and compare them to healthy subjects | comparing diameter (in mm2) of optic nerve in SLE patients and compare them to healthy subjects | over 1 year |
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to understand the epidemiological status of Fabry in patients with hypertrophic cardiomyopathy or left ventricular hypertrophy through multi-center early identification of high-risk patients in cardiology according to high-risk profiles, supplemented by DBS (dried blood disc) screening tools, and to explore the screening and diagnosis methods of patients with Fabry disease in cardiology, so as to promote the early identification, diagnosis and treatment of Fabry in cardiology.

Official Title
-----------------
Screening Patients With Fabry Disease in Patients With Hypertrophic Cardiomyopathy or Left Ventricular Hypertrophy

Conditions
-----------------
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Fabry Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet diagnostic criteria for hypertrophic cardiomyopathy (HCM) in adults (age ≥ 18 years):Imaging of one or more left ventricular segments reveals a maximum end-diastolic ventricular wall thickness of ≥15 mm or end-diastolic ventricular septal thickness or posterior left ventricular wall thickness of ≥13 mm on either cardiac imaging at rest. Exclusion Criteria: 1. Identification of hypertrophic cardiomyopathy caused by mutations in pathogenic genes; 2. Identify the cause of left ventricular hypertrophy (LVH); 3. Aortic valve or mitral valve lesions that can cause hemodynamic changes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnosis of Fabry disease | Clinicians can identify high-risk patients in cardiology at an early stage according to the high-risk profile developed in this study, supplemented by the DBS (dried blood disc) screening tool, and diagnose and treat Fabry disease as early as possible through the established screening pathway for high-risk patients with Fabry disease in cardiology. | 1 year |
Assessing the Effectiveness of BFA as a Non-pharmacologic Pain Management Intervention: A Randomised Sham Controlled Study

Study Overview
=================
Brief Summary
-----------------
This is a randomized sham controlled study that will include patients hospitalized in the internal medicine department and the orthopedics department at Bnei Zion Hospital presenting with pain from various sources with an NRS level equal to or above 4.

Detailed Description
-----------------
All patients will complete pain assessment according NSR and ESAS after treatment ( SHAM or BFA) one hour before and every 24 hours until discharge. If there was no sufficient improvement in pain within 24 hours (decrease of 1.5 points or more in NRS) - additional acupuncture will be performed in the contralateral ear and repeated assessments as above.

Official Title
-----------------
Assessing the Effectiveness of BFA as a Non-pharmacologic Pain Management Intervention: A Randomised Sham Controlled Study in Participants Who Hospitalized in Department of Internal Medicine

Conditions
-----------------
Assessing the Effectiveness of BFA as a Non-pharmacologic Pain Management Intervention: A Randomised Sham Controlled Study

Intervention / Treatment
-----------------
* Other: accupunture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -1.Pain of skeletal muscle origin (Musculoskeletal MSK)/rheumatological/orthopedic syndromes 2.Visual Analog Score (VAS) grade 4 or higher before receiving the treatment. 3.Eligible to participate in the study according to the assessment of the investigator Exclusion Criteria: Pain syndromes of non-muscular bony/rheumatological/orthopedic origin Planned an MRI next week An infectious process in the ear planned for acupuncture or a history of sensitivity to metal have any participant condition that ' according to the Investigator ' could interfere with the conduct of the trial -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sham Comparator: sham controlled arm<br> | Other: accupunture<br>* BFA<br>|
| Active Comparator: battlefield acupunture<br> | Other: accupunture<br>* BFA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy of BFA | Evaluating the analgesic efficacy of BFA in addition to the standard treatment for pain - Standard of care (SOC) to reduce pain in patients hospitalized in the internal and orthopedic department who experience pain of moderate intensity and above compared to SHAM BFA. | two years |
YOGA-CF (Yoga Outcomes Get Assessed in Cystic Fibrosis)

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to investigate the effects of yoga participation for adults with cystic fibrosis. The main question it aims to answer is: does participation in yoga affect health-related quality of life for adults with cystic fibrosis? Researchers will compare a group completing a 12-week yoga programme alongside usual cystic fibrosis care, to a group completing usual care alone to see if the addition of yoga effects health-related quality of life.

Official Title
-----------------
Yoga Outcomes Get Assessed in Cystic Fibrosis

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Other: Yoga


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of CF (confirmed by standard criteria; (Farrell et al. 2017)) Sixteen years of age or over Home internet access Ability to complete questionnaires in English Stable CF disease as judged by the investigator, a senior CF clinician Exclusion Criteria: Inability to consent for treatment or measurement Current participation in another interventional study Current haemoptysis (greater than streaking in the sputum) Known pregnancy at time of recruitment Forced expiratory volume in 1 second (FEV1) below 30% predicted at baseline Use of ambulatory oxygen therapy, long-term oxygen therapy (LTOT) or non-invasive ventilation Current regular participation in yoga practice Current neurological or musculoskeletal injury which would prevent completion of yoga Diagnosis of osteoporosis (bone density Z score <-2.5) or history of spontaneous spinal fractures Uncontrolled gastroesophageal reflux Acute pulmonary exacerbation within 28 days of screening

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Yoga intervention group<br>12 week programme of yoga - encouraged to complete 1 live class and one pre-recorded class a week. Participants will continue with usual cystic fibrosis care. | Other: Yoga<br>* Yoga classes<br>|
| No Intervention: Control group<br>Usual cystic fibrosis care. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health- related quality of life - measured by the respiratory domain of the Cystic Fibrosis Questionnaire - Revised. | CFQ-R respiratory domain | Baseline, 12 and 24-weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Yoga
Eye Mask on Sleep Quality and Tear Layer Function in Patients With Dry Eye Disease

Study Overview
=================
Brief Summary
-----------------
This randomized clinical trial (RCT) was aimed to determine the effects of eye masking on sleep quality and tear layer function in patients with dry eye disease. In this regard, a total of 34 patients with dry eye disease aged between 20 to 35 years old will be participated. They will be randomly divided into case and control (n=17) groups. Patients in the case group will be instructed to wear the eye mask as long as two weeks and the controls will be recommended to not wear it at the same time. Afterwards, the eye mask application will be cross- over for the next 2 hours between the two groups. Tear layer will be investigated in baseline and repeated in both follow- ups of weeks 2 and 4, either quantitatively and qualitatively, by using Schirmer and TBUT tests. Furthermore, the sleep quality will be checked by the PSQI test.

Official Title
-----------------
The Effects of Eye Mask on Increasing the Sleep Quality and Tear Layer Function in Patients With Dry Eye Disease

Conditions
-----------------
Dry Eye Disease

Intervention / Treatment
-----------------
* Device: Eye mask


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with dry eye disease according to the OSDI test Exclusion Criteria: Patients with eye disease except dry eye Patients using systemic and ophthalmic drugs Patients using sleeping and sedative pills

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Eye mask users<br>The eyes of the patients will be defined as the intervention | Device: Eye mask<br>* The 3D eye mask with the ability to adjust for different faces and eliminate light<br>|
| No Intervention: Non eye mask users<br>The eyes of the patients will be defined as the controls | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of using eye mask on tear layer functions between baseline and follow- ups of weeks 2 and 4 in patients with dry eye | Tear film function is measured quantitatively and qualitatively by the Schirmer (based on millimeters) and TBUT ( based on seconds) test | between baseline and follow- ups of weeks 2 and 4 | 
| The effect of using eye mask on sleep quality between baseline and follow- ups of weeks 2 and 4 in patients with dry eye | Sleep quality is measured by PSQI test based on the obtained score | between baseline and follow- ups of weeks 2 and 4 |